Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGN Allergan	$193.02	$190.89	$114.27 ▼ $202.21	$63.50B	1.2	4.01 million shs	12.44 million shs
GPS GAP		$23.22	$9.38 ▼ $30.75	$9.21B	2.38	7.63 million shs	7.17 million shs
LLY Eli Lilly and Company	$845.40 +0.7%	$734.60	$623.78 ▼ $937.00	$800.13B	0.47	4.13 million shs	3.64 million shs
PFE Pfizer	$26.45 -3.4%	$24.67	$20.92 ▼ $30.43	$150.38B	0.55	46.83 million shs	62.44 million shs
VIRI Virios Therapeutics	$6.41 -0.2%	$5.11	$0.13 ▼ $1.04	$123.44M	1.58	1.05 million shs	123,846 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGN Allergan	0.00%	0.00%	0.00%	0.00%	0.00%
GPS GAP	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.00%	+15.97%	+15.71%	+8.75%	-5.26%
PFE Pfizer	0.00%	+15.22%	+10.10%	+8.46%	-4.25%
VIRI Virios Therapeutics	0.00%	+16.12%	+28.20%	+33.54%	+3,688.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGN Allergan	$193.02	$190.89	$114.27 ▼ $202.21	$63.50B	1.2	4.01 million shs	12.44 million shs
GPS GAP		$23.22	$9.38 ▼ $30.75	$9.21B	2.38	7.63 million shs	7.17 million shs
LLY Eli Lilly and Company	$845.40 +0.7%	$734.60	$623.78 ▼ $937.00	$800.13B	0.47	4.13 million shs	3.64 million shs
PFE Pfizer	$26.45 -3.4%	$24.67	$20.92 ▼ $30.43	$150.38B	0.55	46.83 million shs	62.44 million shs
VIRI Virios Therapeutics	$6.41 -0.2%	$5.11	$0.13 ▼ $1.04	$123.44M	1.58	1.05 million shs	123,846 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGN Allergan	0.00%	0.00%	0.00%	0.00%	0.00%
GPS GAP	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.00%	+15.97%	+15.71%	+8.75%	-5.26%
PFE Pfizer	0.00%	+15.22%	+10.10%	+8.46%	-4.25%
VIRI Virios Therapeutics	0.00%	+16.12%	+28.20%	+33.54%	+3,688.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGN Allergan	0.00	N/A	N/A	N/A
GPS GAP	0.00	N/A	N/A	N/A
LLY Eli Lilly and Company	2.64	Moderate Buy	$938.94	11.07% Upside
PFE Pfizer	2.37	Hold	$28.41	7.42% Upside
VIRI Virios Therapeutics	2.00	Hold	$5.00	-22.00% Downside

Current Analyst Ratings Breakdown

Latest VIRI, AGN, LLY, PFE, and GPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/3/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$1,028.00 ➝ $1,023.00
10/3/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$28.00 ➝ $30.00
10/1/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$28.00
10/1/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$700.00 ➝ $800.00
9/27/2025	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
9/27/2025	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
9/17/2025	LLY Eli Lilly and Company	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$970.00 ➝ $830.00
9/16/2025	LLY Eli Lilly and Company	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$1,100.00 ➝ $1,050.00
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00

(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGN Allergan	$16.09B	3.95	$36.70 per share	5.26	$177.28 per share	1.09
GPS GAP	$15.00B	0.00	N/A	8.11	$7.00 per share	0.00
LLY Eli Lilly and Company	$53.26B	15.02	$14.33 per share	59.00	$15.03 per share	56.25
PFE Pfizer	$63.83B	2.36	$4.22 per share	6.27	$15.62 per share	1.69
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGN Allergan	-$5.27B	$17.64	N/A	10.65	1.63	-15.44%	8.46%	5.31%	N/A
GPS GAP	$502M	$1.80	13.64	0.00	1.40	4.52%	27.57%	6.30%	N/A
LLY Eli Lilly and Company	$10.59B	$15.30	55.25	27.17	1.17	25.91%	92.72%	16.89%	10/30/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	14.07	8.73	0.88	16.84%	21.42%	9.12%	11/4/2025 (Estimated)
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A

Latest VIRI, AGN, LLY, PFE, and GPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/30/2025	Q3 2025	LLY Eli Lilly and Company	$6.42	N/A	N/A	N/A	$16.09 billion	N/A
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGN Allergan	$2.96	1.53%	N/A	16.78%	N/A
GPS GAP	$0.60	2.55%	N/A	33.33%	2 Years
LLY Eli Lilly and Company	$6.00	0.71%	N/A	39.22%	11 Years
PFE Pfizer	$1.72	6.50%	N/A	91.49%	16 Years
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGN Allergan	0.31	1.01	0.84
GPS GAP	0.55	1.50	0.80
LLY Eli Lilly and Company	1.86	1.28	1.00
PFE Pfizer	0.65	1.16	0.85
VIRI Virios Therapeutics	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGN Allergan	83.91%
GPS GAP	58.81%
LLY Eli Lilly and Company	82.53%
PFE Pfizer	68.36%
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
AGN Allergan	0.08%
GPS GAP	30.81%
LLY Eli Lilly and Company	0.13%
PFE Pfizer	0.06%
VIRI Virios Therapeutics	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGN Allergan	17,400	329.00 million	N/A	Optionable
GPS GAP	85,000	375.07 million	259.51 million	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
VIRI Virios Therapeutics	5	19.26 million	16.91 million	Optionable

VIRI, AGN, LLY, PFE, and GPS Headlines

Recent News About These Companies

Virios Therapeutics (NASDAQ:VIRI) Stock Price Up 4.1% - What's Next?

September 23, 2025 | marketbeat.com

Digital acceptance and commitment therapy for fibromyalgia – Authors' reply

June 13, 2025 | thelancet.comT

Dogwood Therapeutics Inc (DWTX)

March 16, 2025 | investing.com

Dogwood prices 578,950 shares at $8.26 in registered direct offering

March 13, 2025 | markets.businessinsider.com

Dogwood announces conversion of existing $19.5M in debt to equity

March 12, 2025 | markets.businessinsider.com

DWTX Stock trading resumes

February 11, 2025 | markets.businessinsider.com

Dogwood Therapeutics, Inc. (DWTX)

February 2, 2025 | finance.yahoo.com

DWTX Stock trading halted, volatility trading pause

January 28, 2025 | markets.businessinsider.com

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

January 23, 2025 | msn.com

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

January 21, 2025 | markets.businessinsider.com

Polluted communities hold their breath as companies struggle with California’s diesel truck ban

December 10, 2024 | apnews.comA

Dogwood Therapeutics faces potential Nasdaq delisting

November 23, 2024 | uk.investing.com

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

November 18, 2024 | markets.businessinsider.com

Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

November 18, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary

November 16, 2024 | benzinga.com

DWTX: Phase 2 Long COVID Results Expected Soon

November 12, 2024 | msn.com

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

November 10, 2024 | markets.businessinsider.com

Dogwood Therapeutics Reports Q3 2024 Financial Results

November 9, 2024 | markets.businessinsider.com

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 8, 2024 | markets.businessinsider.com

Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 31, 2024 | finanznachrichten.de

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VIRI, AGN, LLY, PFE, and GPS Company Descriptions

Allergan NYSE:AGN

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

GAP NYSE:GPS

The Gap, Inc. operates as an apparel retail company. The company offers apparel, accessories, and personal care products for men, women, and children under the Old Navy, Gap, Banana Republic, and Athleta brands. Its products include adult apparel and accessories; and fitness and lifestyle products for use in yoga, training, sports, travel, and everyday activities for women and girls. The company offers its products through company-operated stores, franchise stores, websites, and third-party arrangements. It has franchise agreements to operate Old Navy, Gap, Banana Republic, and Athleta stores and websites in Asia, Europe, Latin America, the Middle East, and Africa. The Gap, Inc. was incorporated in 1969 and is headquartered in San Francisco, California.

Eli Lilly and Company NYSE:LLY

$845.40 +5.53 (+0.66%)

Closing price 03:59 PM Eastern

Extended Trading

$843.40 -2.00 (-0.24%)

As of 05:07 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer NYSE:PFE

$26.45 -0.92 (-3.36%)

Closing price 03:59 PM Eastern

Extended Trading

$26.45 0.00 (0.00%)

As of 05:07 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Virios Therapeutics NASDAQ:VIRI

$6.41 -0.01 (-0.16%)

As of 10/3/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIRI, AGN, LLY, PFE, and GPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIRI, AGN, LLY, PFE, and GPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIRI, AGN, LLY, PFE, and GPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIRI, AGN, LLY, PFE, and GPS Company Descriptions

Allergan NYSE:AGN

GAP NYSE:GPS

Eli Lilly and Company NYSE:LLY

Pfizer NYSE:PFE

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools